Fulltext

Impacts of Curcumin Supplementation on Cardiometabolic Risk Factors in Patients With Polycystic Ovary Syndrome: A Systematic Review and Dose-Response Meta-Analysis

Mohammadi S 1 , Ziaei S 2 , Morvaridi M 3 , Hasani M 4 , Mirtaheri E 5 , Farsi F 6 Show all authors , Ebrahimi S 7 , Daneshzad E 8 , Heshmati J 9

Affiliations 

  • 1 Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
  • 2 Departemt of Anesthesia, Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran
  • 3 School of Public Health Iran University of Medical Sciences Tehran Iran
  • 4 Department of Nutritional Sciences School of Health, Golestan University of Medical Sciences Gorgan Iran
  • 5 Department of Human Sciences Human Nutrition Program, The Ohio State University Columbus Ohio USA
  • 6 Minimally Invasive Surgery Research Center Iran University of Medical Sciences Tehran Iran
  • 7 Institute for Physical Activity and Nutrition School of Exercise and Nutrition Sciences, Deakin University Geelong VIC Australia
  • 8 Non-Communicable Diseases Research Center Alborz University of Medical Sciences Karaj Iran
  • 9 University of Ottawa Heart Institute Ottawa Canada
Health Sci Rep, 2025 Mar;8(3):e70525.
PMID: 40041784 DOI: 10.1002/hsr2.70525

Abstract

BACKGROUND AND AIM: Patients with polycystic ovary syndrome (PCOS) commonly have cardiometabolic risk factors. Oxidative stress (OS) significantly contributes to the development of cardiometabolic diseases. Curcumin (CUR) exhibits antioxidant properties that aid in OS regulation. This systematic review and dose-response meta-analysis of randomized clinical trials (RCTs) evaluated the effects of CUR supplementation on cardiometabolic risk factors in women with PCOS.

METHODS: A systematic search across various databases was implemented to identify eligible RCTs published until January 2024. A meta-analysis was conducted employing a random-effects model.

RESULTS: Eight RCTs were included in the meta-analysis. It was indicated that CUR supplementation substantially reduced fasting blood sugar (FBS) (standardized mean difference [SMD]: -0.40 mg/dL, 95% confidence interval [CI]: -0.59, -0.21; p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications